YOLFTbeta
Neuropace Inc

Neuropace Inc

NPCE · NASDAQ · Healthcare / Medical Devices

7.56USD-4.46 (-37.10%)

Price History

Full chart

Market Stats

Previous Close12.02
Open6.25
Day Range5.46 – 7.71
52-Week Range9.22 – 19.60
Volume6.09M
Market Cap482.60M
P/E (TTM)0.00
Forward P/E158.73
EPS-0.47
Dividend Yield0.00%
Beta1.95
50-Day Avg14.51
200-Day Avg15.40

About

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Joel D. Becker
  • Employees220
  • Headquarters455 North Bernardo Avenue, Mountain View, CA, United States, 94043, USA
  • Websitehttps://www.neuropace.com

Leadership

  • Mr. Joel D. BeckerCEO, President & Director · b. 1968
  • Mr. Patrick F. WilliamsChief Financial Officer · b. 1973
  • Dr. Martha J. Morrell M.D.Chief Medical Officer · b. 1957
  • Mr. Dylan St. JohnChief of Operations & Development
  • Mr. Scott R. SchaperHead of Investor Relations
  • Ms. Leah AkinGeneral Counsel & Corporate Secretary
  • Ms. Katie KellerVice President of Marketing
  • Mr. Chris ReeseSenior Vice President of Sales
  • Ms. Amy TreadwellVice President of Human Resources
  • Ms. Julie HsuVP & Controller

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue36.97M41.14M45.18M45.52M65.42M79.91M99.99M
Growth (%)-+11.27%+9.83%+0.75%+43.72%+22.14%+25.13%
Cost of Revenue10.51M10.87M11.75M13.03M17.30M20.82M22.77M
Gross Profit26.46M30.27M33.44M32.49M48.12M59.09M77.22M
Gross Margin71.58%73.59%74.00%71.38%73.56%73.94%77.23%
Operating Expense48.49M43.32M57.17M73.29M75.30M80.76M93.56M
Operating Income-22.03M-13.05M-23.74M-40.79M-27.17M-21.67M-16.34M
Operating Margin-59.59%-31.72%-52.54%-89.62%-41.54%-27.12%-16.34%
EBITDA-20.07M-12.48M-28.37M-36.57M-22.83M-16.57M-12.06M
EBITDA Margin-54.28%-30.34%-62.80%-80.33%-34.90%-20.74%-12.06%
Net Income-29.97M-24.28M-36.08M-47.08M-32.96M-27.14M-21.46M
Net Income Margin-81.07%-59.02%-79.85%-103.43%-50.38%-33.97%-21.47%
R&D18.29M15.70M18.21M21.95M20.78M23.65M27.89M
R&D as % of Total Revenue49.48%38.15%40.30%48.21%31.76%29.60%27.89%
Interest Expense9.48M11.49M7.41M7.53M8.52M8.80M7.46M
Interest Expense % of Total Revenue25.65%27.92%16.40%16.54%13.02%11.01%7.46%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.09M55.95M133.56M114.11M107.65M94.65M105.56M
Total Liabilities150.44M203.78M60.06M79.33M87.00M86.63M86.53M
Total Equity-129.35M-147.83M73.50M34.78M20.65M8.01M19.03M
Cash4.12M26.39M19.19M6.61M18.06M13.43M21.69M
Total Debt62.80M52.86M49.85M69.77M72.39M73.34M70.84M
Net Debt58.68M26.47M30.66M63.16M54.34M59.91M49.15M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-25.03M-21.61M-24.58M-36.87M-19.70M-17.95M-11.01M
Investing Cash Flow3.62M-10.77M-85.40M23.80M23.03M8.99M-332.00K
Financing Cash Flow21.37M55.01M102.53M490.00K8.13M4.33M19.60M
Capital Expenditure468.00K62.00K384.00K603.00K173.00K306.00K332.00K
Free Cash Flow-25.49M-21.67M-24.96M-37.47M-19.87M-18.25M-11.34M
FCF to OCF101.87%100.29%101.56%101.64%100.88%101.70%103.02%

Earnings

Report DateMar 24, 2021Jun 3, 2021Aug 12, 2021Nov 10, 2021Mar 10, 2022May 12, 2022Aug 11, 2022Nov 8, 2022Mar 2, 2023May 4, 2023Aug 8, 2023Nov 6, 2023Mar 5, 2024May 8, 2024Aug 13, 2024Nov 12, 2024Mar 3, 2025May 13, 2025Aug 12, 2025Nov 4, 2025Mar 3, 2026May 13, 2026Aug 11, 2026Nov 3, 2026
EPS Estimate0.00-0.28-0.34-0.30-0.33-0.44-0.44-0.53-0.49-0.44-0.46-0.41-0.32-0.32-0.30-0.27-0.22-0.24-0.22-0.19-0.15-0.23-0.19-0.14
EPS Actual-0.17-32.73-0.48-0.34-0.44-0.47-0.52-0.48-0.45-0.41-0.36-0.28-0.23-0.32-0.26-0.19-0.18-0.21-0.26-0.11-0.08-0.20-0.18-
Surprise--11589.29%-41.18%-13.33%-33.33%-6.82%-18.18%9.43%8.16%6.82%21.74%31.71%28.13%0.00%13.33%29.63%19.39%12.50%-18.18%42.11%46.67%13.59%5.26%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap482.60M
Enterprise Value507.35M
Trailing P/E0.00
Forward P/E158.73
Price / Sales4.51
Price / Book41.16
EPS-0.47
Book Value0.347
Revenue (TTM)106.99M
Gross Profit (TTM)82.79M
EBITDA-11.88M
Profit Margin-17.86%
Operating Margin-22.53%
Return on Equity-103.27%
Return on Assets-7.47%
Shares Outstanding34.32M
Shares Float25.42M
Beta1.95
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 20.00
  • Strong Buy
    6
  • Buy
    2

Ownership Breakdown

Institutions
97.33%
Insiders
4.47%
Retail / Other
0.00%

Top Institutional Holders

  • Polar Capital Holdings PLC
    3.30M9.61%
  • Soleus Capital Management, L.P.
    2.91M8.48%
  • First Light Asset Management, LLC
    2.86M8.34%
  • Morgan Stanley - Brokerage Accounts
    2.57M7.48%
  • BlackRock Inc
    2.35M6.84%
  • Orbimed Advisors LLC
    2.10M6.11%
  • Driehaus Capital Management LLC
    1.45M4.23%
  • Vanguard Capital Management, LLC
    1.12M3.27%
  • Deutsche Bank AG
    932.09K2.72%
  • Armistice Capital, LLC
    692.00K2.02%
  • Geode Capital Management, LLC
    618.12K1.80%
  • FMR Inc
    553.53K1.61%
  • State Street Corp
    497.55K1.45%

Top Fund Holders

  • Polar Capital Healthcare Opports Inc
    2.89M8.41%
  • Vanguard MStar Total Stk Mkt Idx Invest
    908.48K2.65%
  • Xtrackers MSCI World Swap ETF 1C
    737.12K2.15%
  • iShares Russell 2000 ETF
    678.28K1.98%
  • Heptagon Driehaus US Micro Cap Eq C$ Acc
    438.31K1.28%
  • Polar Capital Glb Healthcare Ord
    409.81K1.19%
  • Fidelity Small Cap Growth
    361.86K1.05%